Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.

نویسندگان

  • Vaishali Sanchorawala
  • Karen Quillen
  • J Mark Sloan
  • Nancy T Andrea
  • David C Seldin
چکیده

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

AL amyloidosis in a young adult: remission with autologous stem cell transplantation.

Autologous stem cell transplant is one of the therapies employed in the treatment of primary amyloidosis or AL. The authors report on a 46-year-old patient with bilateral periorbital hematomas, macroglossia who presented, during the investigation, IgG-Kappa paraprotein in serum. The diagnosis of primary amyloidosis or AL was confirmed and the treatment proposed consisted of high-dose melphalan ...

متن کامل

Chemotherapy for renal AL amyloidosis: treatment results and outcomes in 49 patients from a single center

Introduction AL amyloidosis is actually known to be the most common form of systemic amyloidosis in the Western countries [1, 2]. In this particular type of amyloidosis monoclonal immunoglobulin light chains, produced by plasma cell clone, undergo aggregation and form amyloid deposits, almost always systemically, and kidneys are one of the most frequent sites of amyloid deposition [3, 4, 5]. AL...

متن کامل

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma

BACKGROUND High-dose melphalan (200 mg/m(2)) with autologous stem cell transplantation (ASCT) is the standard treatment for young patients with multiple myeloma (MM). However, the response rates after ASCT are often unsatisfactory. We performed a pilot study by using bortezomib-melphalan as conditioning regimen for ASCT in Korean patients with MM. METHODS The conditioning regimen consisted of...

متن کامل

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

BACKGROUND High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation has been reported to provide higher response rates and better overall survival than standard chemotherapy in immunoglobulin-light-chain (AL) amyloidosis, but these two strategies have not been compared in a randomized study. METHODS We conducted a randomized trial comparing high-dose intravenous m...

متن کامل

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

BACKGROUND AND OBJECTIVES High-dose melphalan and autologous stem cell transplantation is currently the treatment of choice for selected patients with AL amyloidosis; however, new treatments are needed for patients who are ineligible for or relapse after this procedure. Bortezomib is a proteasome inhibitor with proven activity in multiple myeloma, and the addition of dexamethasone results in su...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Haematologica

دوره 96 12  شماره 

صفحات  -

تاریخ انتشار 2011